Clinical Trials
- Colorectal Cancer, Stomach and Esophagus
An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated With Imatinib
- Ages18 years and older
- GenderBoth
- Brain and Other Nervous System Cancers, Colorectal Cancer, Stomach and Esophagus, Lung Cancer, Pancreatic Cancer, Phase 1 Cancers
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors
- Liver, Digestive System
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)
- Ages18 years - 75 years
- GenderBoth
- Digestive System
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
- Ages12 years - 75 years
- GenderBoth
- Colorectal Cancer, Gynecological Cancers, Stomach and Esophagus, Kidney Cancer, Head and Neck Cancers, Liver Cancer, Lung Cancer, Melanoma, Thyroid and Other Endocrine Cancers, Other Cancers, Pancreatic Cancer, Prostate Cancer, Phase 1 Cancers, Bladder Cancer
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Stomach and Esophagus, Pancreatic Cancer
A Phase Ib, Open-Label, Multicenter Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
- Colorectal Cancer, Stomach and Esophagus, Liver Cancer, Pancreatic Cancer
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors
- Digestive System
The OPTIMIZE Trial
- Ages18 years - 80 years
- GenderBoth
- Digestive System
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
- Ages18 years - 75 years
- GenderBoth
- Digestive System
Operative Versus Non-Operative Management for Appendicitis With Abscess or Phlegmon
- Ages18 years and older
- GenderBoth